Merck & Co., Inc. vs iShares US Power Infrastructure ETF — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while iShares US Power Infrastructure ETF trades at $25.47 (market cap $446.54M). The key difference: Merck & Co., Inc. is far larger — about 786.7× iShares US Power Infrastructure ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while iShares US Power Infrastructure ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and iShares US Power Infrastructure ETF for 14 Days on average.
| MRK | POWR | |
|---|---|---|
Market Cap | $351.28B | $446.54M |
Volume | 7,969,665 | 160,852 |
Sector | Health | Sector/Thematic |
52-Week High | $156.43 | $28.22 |
52-Week Low | $82.49 | $23.20 |
Typical Hold Time | 98 Days | 14 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01 billion in 2025, and net income reached $18.25 billion. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing stakes.
The outlook for Merck is supported by analyst consensus with a $158.78 price target and 68% buy ratings, but risks include high valuation multiples like a P/E of 113.9 and competitive pressures in the pharma sector. The stock's investment appeal hinges on pipeline execution and integration of acquisitions amid a challenging technical backdrop.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →iShares U.S. Power Infrastructure ETF seeks exposure to U.S. companies involved in power infrastructure. Its holdings may include electric utilities, transmission and distribution businesses, and electrical equipment providers.
Read more on POWR →